Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | AXL | P30530 | 2/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 11/20 | 0.39 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.37 |
| ▸ | KCNK18 | Q7Z418 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21749277 | 0.90 | ABCG2 (0.48) | PDK2AXLABCG2TAS2R14ABCB1 | |
| SCHEMBL20552813 | 0.84 | ABCG2 (0.46) | PDK2AXLABCG2TAS2R14ABCB1 | |
| SCHEMBL25787264 | 0.78 | SMN1; SMN2 (0.45) | — | |
| SCHEMBL25787897 | 0.78 | ABCG2 (0.38) | ABCG2TAS2R14ABCB1KCNK18 | |
| SCHEMBL25787274 | 0.77 | MAPT (0.53) | ABCG2 | |
| SCHEMBL25787694 | 0.77 | LMNA (0.37) | ABCG2TAS2R14 | |
| SCHEMBL25787911 | 0.76 | ABCG2 (0.39) | ABCG2TAS2R14ABCB1KCNK18 | |
| SCHEMBL25787720 | 0.76 | KMT2A (0.42) | ABCG2ABCB1 | |
| SCHEMBL25787068 | 0.75 | SMN1; SMN2 (0.40) | ABCG2TAS2R14ABCB1 | |
| SCHEMBL21749269 | 0.75 | ABCG2 (0.46) | ABCG2TAS2R14ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | TEAD1, TEAD4, TEAD2 | PDK2 3742/4885AXL 4847/4885ABCG2 2217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.